Healing & Tissue Repair
BPC-157
Body Protection Compound-157
Also known as: PL 14736 Bepecin
Mechanism & research context
Studied in animals for effects on angiogenesis, tendon/ligament cell migration, and nitric-oxide pathways. Mechanism in humans is not established.
Origin: Synthetic 15-amino-acid sequence derived from a partial segment of a human gastric juice protein.
Safety flags
3 flags-
High severity no_human_data
No adequately powered human clinical trial data has been published for BPC-157 as of the most recent systematic review.
-
High severity regulatory_action
Placed on FDA "difficult to compound" category. Cannot be legally compounded in 503A/503B pharmacies in the United States.
Source ↗ -
Moderate severity theoretical_risk
Angiogenic activity carries theoretical concern in undiagnosed malignancies — no human safety data rules this out.
Research papers
17 recordsCitation links route to PubMed, Europe PMC, and PMC. Presence of a study is not endorsement. Records are refreshed from PubMed on a regular cadence; rows marked “Live search link” will resolve to a current PubMed search until a full citation has been ingested.
-
· 2026 Open access
Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157—A Review
-
· 2026 Open access
Conventional Antiarrhythmics Class I–IV, Late INa Inhibitors, IKs Enhancers, RyR2 Stabilizers, Gap Junction Modulators, Atrial-Selective Antiarrhythmics, and Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Therapy in Arrhythmias
-
· 2026 Open access
Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System-Triple NO-Agent Approach in Rats.
-
· 2026 Open access
Fourier Transform Infrared Spectroscopic Characterization of Aortic Wall Remodeling by Stable Gastric Pentadecapeptide BPC 157 After Unilateral Adrenalectomy in Rats.
-
· 2026
Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157-A Review.
-
· 2026
Stable Gastric Pentadecapeptide BPC 157 as a Therapy of Severe Electrolyte Disturbances in Rats.
-
· 2026 Open access
From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management.
-
· 2026 Open access
Cytoprotection as a Unifying Strategy for Hemorrhage and Thrombosis: The Role of BPC 157 and Related Therapeutics.
-
· 2025
BPC-157 Binding to SH3 Domains and Activation of Src Family Kinases: In Silico Modeling and Fluorescent Fusion Protein Production
-
· 2025
BPC-157 Predicted to Bind SH3 Domains and Activate Src Family Kinases: In Silico Modeling and Fluorescent Fusion Protein Validation
-
· 2025 Open access
Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.
-
· 2025
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
-
· 2025 Open access
Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant and is believed to protect the gastro-intestinal tract (GIT).
-
· 2025
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.
-
· 2025 Open access
BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. <i>Pharmaceuticals</i> 2025, <i>18</i>, 185.
-
Review · PubMed (NCBI) Live search link
PubMed literature search: BPC-157
Run importer to populate live PubMed records. This placeholder links to a live search.
-
Systematic review · PubMed indexed (systematic review)
A Systematic Review of BPC-157
Systematic review summarizing animal evidence and the absence of adequate human RCT data for BPC-157.
Clinical trials
3 records-
Live search Live search
Live ClinicalTrials.gov search: BPC-157
Condition: See live results
Open on ClinicalTrials.gov ↗ -
NCT02637284 PHASE1 UNKNOWN
Phase I, Pilot Study in Healthy Volunteers, to Assess the Safety and Pharmacokinetics of PCO-02, Which Active Ingredient is BPC-157, a Penta-deca-peptide From Gastric Source.
Condition: Healthy Volunteers
Sponsor: PharmaCotherapia d.o.o.
Open on ClinicalTrials.gov ↗ -
NCT07437547 PHASE2 RECRUITING
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain Confirmed by MRI
Condition: Hamstring Muscle Strain; Skeletal Muscle Injury
Sponsor: Hudson Biotech
Open on ClinicalTrials.gov ↗
Doses reported in studies
0 recordsNo study-protocol dose records have been curated for BPC-157 yet. Absence of records is not evidence of safety — many peptides lack adequate human-trial data in the first place.
Records here are populated from public sources only (ClinicalTrials.gov protocol summaries and FDA-approved labels) and must cite a verifiable source URL. They are not added from forum posts, vendor pages, anecdotal write-ups, or social media.
These entries describe what was studied. They do not tell you what to take, how to reconstitute anything, how to fill a capsule, how often to administer, or where to obtain a compound. If you are considering use of BPC-157, those decisions belong with a licensed clinician working from the full label or trial record — not from this summary.
Why this page does not list a dose for self-use
The "Doses reported in studies" section above (when populated) describes what was administered in a cited study or label, under medical supervision, in a specific population. It is not a dosing guide for self-use. Separately, we do not publish anecdotal or community-reported dose ranges, administration methods, vial concentrations, or capsule masses for BPC-157. Anecdotal figures for unapproved compounds are not harm-reduction data: they lack denominators for adverse events, cannot account for individual physiology or compound purity, and normalise unsupervised use. See the safety policy for the full reasoning.
If this compound has an FDA-approved label
If a label exists, the regulator-reviewed dosing and administration information is there — read it in the context of a prescriber's evaluation.
Questions worth bringing to a clinician
- What is the evidence for this compound in someone with my history?
- What are the realistic, regulator-reviewed alternatives?
- What would you monitor, and what would make you stop?
If you have already taken a peptide and feel unwell: contact emergency services. In the United States, Poison Control is reachable 24/7 at 1-800-222-1222. Do not wait for a community thread.